2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(2-(4-(3-((4-((4-(1-isopropyl-2-methyl-1H-imidazole-5-yl)pyrimidin-2-yl)amino)phenyl)sulfonyl)propyl)-1H-1,2,3-triazol-1-y1)ethoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione

ID: ALA5093560

PubChem CID: 166634128

Max Phase: Preclinical

Molecular Formula: C43H51N11O9S

Molecular Weight: 898.02

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1ncc(-c2ccnc(Nc3ccc(S(=O)(=O)CCCc4cn(CCOCCOCCOCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)nn4)cc3)n2)n1C(C)C

Standard InChI:  InChI=1S/C43H51N11O9S/c1-28(2)53-29(3)46-26-37(53)34-15-16-45-43(48-34)47-30-9-11-32(12-10-30)64(59,60)25-5-6-31-27-52(51-50-31)18-20-62-22-24-63-23-21-61-19-17-44-35-8-4-7-33-39(35)42(58)54(41(33)57)36-13-14-38(55)49-40(36)56/h4,7-12,15-16,26-28,36,44H,5-6,13-14,17-25H2,1-3H3,(H,45,47,48)(H,49,55,56)

Standard InChI Key:  AKHSXHXLQGTLRL-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 64 70  0  0  0  0  0  0  0  0999 V2000
   16.6991   -7.1712    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.4855   -7.9710    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   17.2850   -7.7560    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.2676   -4.6088    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.5971   -4.1274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9432   -4.5067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2894   -4.1274    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.6355   -4.5067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9817   -4.1274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3278   -4.5067    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6701   -4.1274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0217   -4.5059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3649   -4.1323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3649   -3.3726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0193   -2.9973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6701   -3.3720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8081   -4.6401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0753   -4.4446    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.1175   -5.3316    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.8691   -5.2453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4025   -5.7786    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7421   -5.9815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1175   -6.6393    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7421   -7.2931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9875   -7.2931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6043   -7.9509    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.6043   -6.6393    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.9875   -5.9815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6043   -5.3316    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.0174   -4.2646    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6917   -4.7422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4413   -4.3980    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.1118   -4.8795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8616   -4.5353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5359   -5.0129    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.5464   -5.8377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3353   -6.0835    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8129   -5.4091    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.3190   -4.7466    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.6001   -6.8663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4105   -7.0283    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6753   -7.8110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7504   -8.7557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2018   -9.3745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4661  -10.1566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.2772  -10.3191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8234   -9.6935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5563   -8.9138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5433  -11.1024    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.3547  -11.2635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6169  -12.0491    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.4275  -12.2104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9736  -11.5879    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7035  -10.8016    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.8936  -10.6440    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.6930  -12.9931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2181  -13.6686    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7125  -14.3309    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.4952  -14.0653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.4844  -13.2390    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.1702  -14.5424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.1466  -12.7446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9058  -13.0709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0496  -11.9239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  1  0
  6  5  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  1  0
 12 11  1  0
 13 12  2  0
 13 14  1  0
 15 14  2  0
 16 15  1  0
 11 16  2  0
 17 13  1  0
 17 18  2  0
 19 17  1  0
 20 19  1  0
 20 21  2  0
 20 12  1  0
 22 19  1  0
 22 23  1  0
 24 23  1  0
 25 24  1  0
 25 26  2  0
 27 25  1  0
 28 27  1  0
 28 29  2  0
 22 28  1  0
  4 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 33 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  2  0
 37 38  1  0
 38 39  2  0
 39 35  1  0
 37 40  1  0
 40 41  1  0
 41 42  1  0
 42  2  1  0
  2 43  1  0
 43 44  2  0
 44 45  1  0
 45 46  2  0
 46 47  1  0
 47 48  2  0
 48 43  1  0
 46 49  1  0
 49 50  1  0
 50 51  2  0
 51 52  1  0
 52 53  2  0
 53 54  1  0
 54 55  2  0
 55 50  1  0
 52 56  1  0
 56 57  2  0
 57 58  1  0
 58 59  2  0
 59 60  1  0
 60 56  1  0
 59 61  1  0
 60 62  1  0
 62 63  1  0
 62 64  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5093560

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 898.02

Molecular Weight (Monoisotopic): 897.3592

AlogP: 3.53

#Rotatable Bonds: 23

Polar Surface Area: 243.75

Molecular Species: NEUTRAL

HBA: 18

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 20

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.33

CX Basic pKa: 6.00

CX LogP: 2.32

CX LogD: 2.30

Aromatic Rings: 5

Heavy Atoms: 64

QED Weighted: 0.06

Np Likeness Score: -1.39

References

1. Hati S, Zallocchi M, Hazlitt R, Li Y, Vijayakumar S, Min J, Rankovic Z, Lovas S, Zuo J..  (2021)  AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.,  226  [PMID:34560429] [10.1016/j.ejmech.2021.113849]

2. Gray, N S NS and 12 more authors.  1998-07-24  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.  [PMID:9677190]

3. Kubo, A A and 9 more authors.  1999-12  The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.  [PMID:10632371]

4. Lane, M E ME and 9 more authors.  2001-08-15  A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.  [PMID:11507069]

5. Bramson, H N HN and 20 more authors.  2001-12-06  Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.  [PMID:11728181]

6. Mettey, Yvette Y and 9 more authors.  2003-01-16  Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.  [PMID:12519061]

7. Wang, Yihan Y and 18 more authors.  2003-09-15  Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.  [PMID:12941335]

8. Sayle, Kerry L KL and 16 more authors.  2003-09-15  Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.  [PMID:12941338]

9. Tavares, Francis X FX and 7 more authors.  2004-09-09  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.  [PMID:15341487]

10. Feldman, Richard I RI and 17 more authors.  2005-05-20  Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.  [PMID:15772071]

11. Lin, Ronghui R and 11 more authors.  2005-06-30  1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.  [PMID:15974571]

12. Pennati, Marzia M and 12 more authors.  2005-09  Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.  [PMID:16170024]

13. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N.  2006-03-24  Selectivity and potency of cyclin-dependent kinase inhibitors.  [PMID:16584130]

14. DePinto, Wanda W and 19 more authors.  2006-11  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.  [PMID:17121911]

15. Wyatt, Paul G PG and 22 more authors.  2008-08-28  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.  [PMID:18656911]

16. Jones, Clifford D CD and 18 more authors.  2008-12-15  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.  [PMID:18996007]

17. Squires, Matthew S MS and 7 more authors.  2009-02  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.  [PMID:19174555]

18. Gaisina, Irina N IN and 10 more authors.  2009-04-09  From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.  [PMID:19338355]

19. Hall, Matthew D and 8 more authors.  2009-05-28  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.  [PMID:19397322]

20. Ali, Simak S and 16 more authors.  2009-08-01  The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.  [PMID:19638587]

21. Zarrinkar, Patrick P PP and 15 more authors.  2009-10-01  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).  [PMID:19654408]

22. Aronov, Alex M AM and 20 more authors.  2009-10-22  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.  [PMID:19827834]

23. Angiolini, Mauro M and 7 more authors.  2010-07-15  Structure-based optimization of potent PDK1 inhibitors.  [PMID:20621725]

24. Laha, Joydev K JK and 7 more authors.  2011-04-01  Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.  [PMID:21353545]

25. William, Anthony D AD and 16 more authors.  2012-03-22  Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.  [PMID:22339472]

26. Hole, Alison J and 9 more authors.  2013-02-14  Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.  [PMID:23252711]

27. Cirstea, D D and 15 more authors.  2013-12  Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.  [PMID:23807770]

28. Martin, Mathew P MP, Olesen, Sanne H SH, Georg, Gunda I GI and Schönbrunn, Ernst E.  2013-11-15  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.  [PMID:24007471]

29. Reddy, M V Ramana MV and 12 more authors.  2014-02-13  Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).  [PMID:24417566]

30. Blake, James F JF and 24 more authors.  2014-06-15  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.  [PMID:24813737]

31. Hanan, Emily J EJ and 24 more authors.  2014-12-11  Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.  [PMID:25383627]

32. Paiva, Cody C and 8 more authors.  2015  Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.  [PMID:26606677]

33. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC.  2016-05  Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.  [PMID:26826116]

34. Sonawane, Yogesh A and 5 more authors.  2016-10-13  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.  [PMID:27171036]

35. Coxon, Christopher R and 20 more authors.  2017-03-09  Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.  [PMID:28005359]

36. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

37. Patel, Hetal H and 15 more authors.  2018-06  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.  [PMID:29545334]

38. Wang, Yiting Y and 6 more authors.  2018-07-23  Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.  [PMID:29853338]

39. Zhi, Yanle Y and 9 more authors.  2018-07-15  Discovery of the selective and efficacious inhibitors of FLT3 mutations.  [PMID:29894944]

40. Sánchez-Martínez, Concepción; Lallena, María José; Sanfeliciano, Sonia Gutiérrez and de Dios, Alfonso.  2019-10-15  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).  [PMID:31477350]

41. Teng, Yuou and 10 more authors.  2019-12-01  Recent advances in the development of cyclin-dependent kinase 7 inhibitors.  [PMID:31514062]

42. Tear, Westley F and 16 more authors.  2020-01-23  Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis.  [PMID:31846577]

43. Wu, Tizhi and 6 more authors.  2020-11-25  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.  [PMID:32866383]

Source

Source(1):

• Scientific Literature